Back to results
US 12,384,845 B2Granted
Activatable masked anti-CTLA4 binding proteins
AssigneesXilio Development, Inc., City of Hope
InventorsJohn C. Williams, Margaret Karow
Life of this patent
Estimating the term…
Abstract
The invention provides activatable masked anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) and their use in treating and preventing cancer, as well as compositions and kits comprising the activatable masked anti-CTLA4 binding proteins.
Claims14
A masked antibody, comprising:
- a) an anti-CTLA4 antibody or antigen-binding fragment thereof comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain;
- and
- b) a masking peptide comprising the amino acid sequence of SEQ ID NO:
- 5;
- wherein the masking peptide is linked via a linker comprising a cleavable peptide to
- an amino-terminus of the VL domain;
- wherein the linker comprising a cleavable peptide comprises a cleavable peptide comprising the amino acid sequence of SEQ ID NO:
- 86;
- wherein (a) the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 408, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 409, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 410;
- and the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 411, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 412, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 413;
- or (b) the VL domain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 438, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 439, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 440;
- and the VH domain comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 441, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 442, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 443.
21 more elements
Dependencies are inferred from the claim text.